top of page

ADDRESSING PERVASIVE TREATMENT CHALLENGES IN DERMATOLOGY

Veradermics has cultivated a dermatology-focused pipeline of five novel product candidates for large-market conditions seen in adults and children that are overdue for new treatment approaches including common warts (verruca vulgaris), molluscum contagiosum, alopecia areata, androgenetic alopecia (pattern hair loss), and atopic dermatitis.

We have a rapidly advancing diverse pipeline of first-in-class candidates

Program Indication

MOA Delivery

PRE-IND

PHASE 1

PHASE 2

PHASE 3

VDMN
Common Warts

Candida Antigen Extract
Immunotherapy 
Dissolvable Microarray

VDMC

Molluscum Contagiosum

Topical 
New Chemical Entity
Antiviral

VDAA

Alopecia Areata

Confidential
Topical against 
Clinically Validated Target

VDPHL

Pattern Hair Loss

Confidential 
Oral against 
Clinically Validated Target

VDAD

Atopic Dermatitis

Oral 
New Chemical Entity
Against Clinically Validated Target

bottom of page